Pay in 4 interest-free payments of $5.02 Learn more
Ships within 48 hours · Estimated delivery Oct 22 - Oct 27
Key highlights: Semaglutide (Novo Nordisk) gaining traction against Tirzepatide (Eli Lilly) Semaglutides market share increased to 21% from 13% in just two months Tirzepatide still holds around 79% share of the GLP-1 segment Indias anti-obesity drug market has tripled to over 1,500 crore in the past year Lower pricing, wider physician adoption, and improved availability are helping Novo Nordisk expand its footprint
(28) The crude incidence rates of amputation were 6.1 per 10,000 person-years for GLP-1s, 1.5 for SGLT-2 inhibitors, 4.6 for DPP4-Is, and 1.9 for other agents
He has extensive education, training and experience with awake liposuction and plastic surgery procedures
American Heart Association Newsroom
Dosing process: Similar to semaglutide, tirzepatide starts with a low initial dose that is slowly increased over time
